The U.S. FDA is investigating the death of an 8-year-old boy who received Elevidys, a Sarepta (SRPT) Therapeutics gene therapy for Duchenne muscular dystrophy. The death occurred on June 7, 2025. The FDA has requested and received voluntary suspension of product distribution as it investigates the safety concerns.
Claim 55% Off TipRanks
Trade SRPT with leveragePublished first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SRPT:
- Buy/Sell: Wall Street’s top 10 stock calls this week
- Negative catalysts loom ahead for Sarepta, says H.C. Wainwright
- Carvana upgraded, Ulta Beauty downgraded: Wall Street’s top analyst calls
- Morning Movers: Intel lower following second quarter earnings
- Sarepta receives negative CHMP opinion on Elevidys marketing authorization